Vertex Pharmaceuticals Statistics Share Statistics Vertex Pharmaceuticals has 256.39M
shares outstanding. The number of shares has increased by -0.51%
in one year.
Shares Outstanding 256.39M Shares Change (YoY) -0.51% Shares Change (QoQ) 0% Owned by Institutions (%) 91.92% Shares Floating 255.63M Failed to Deliver (FTD) Shares 1,371 FTD / Avg. Volume 0.08%
Short Selling Information The latest short interest is 4.19M, so 1.63% of the outstanding
shares have been sold short.
Short Interest 4.19M Short % of Shares Out 1.63% Short % of Float 1.84% Short Ratio (days to cover) 4.16
Valuation Ratios The PE ratio is -193.61 and the forward
PE ratio is 17.69.
Vertex Pharmaceuticals's PEG ratio is
1.69.
PE Ratio -193.61 Forward PE 17.69 PS Ratio 9.41 Forward PS 7.3 PB Ratio 6.32 P/FCF Ratio -131.21 PEG Ratio 1.69
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Vertex Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.69,
with a Debt / Equity ratio of 0.11.
Current Ratio 2.69 Quick Ratio 2.35 Debt / Equity 0.11 Debt / EBITDA 3.6 Debt / FCF -2.21 Interest Coverage -7.61
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.81M Profits Per Employee $-87.8K Employee Count 6,100 Asset Turnover 0.49 Inventory Turnover 1.27
Taxes Income Tax 784.1M Effective Tax Rate 315.53%
Stock Price Statistics The stock price has increased by -19.38% in the
last 52 weeks. The beta is 0.44, so Vertex Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.44 52-Week Price Change -19.38% 50-Day Moving Average 450.59 200-Day Moving Average 461.38 Relative Strength Index (RSI) 26.38 Average Volume (20 Days) 1,636,580
Income Statement In the last 12 months, Vertex Pharmaceuticals had revenue of 11.02B
and earned -535.6M
in profits. Earnings per share was -2.08.
Revenue 11.02B Gross Profit 9.49B Operating Income -232.9M Net Income -535.6M EBITDA 486.3M EBIT 279.1M Earnings Per Share (EPS) -2.08
Full Income Statement Balance Sheet The company has 4.57B in cash and 1.75B in
debt, giving a net cash position of 2.82B.
Cash & Cash Equivalents 4.57B Total Debt 1.75B Net Cash 2.82B Retained Earnings 9.61B Total Assets 24.04B Working Capital 6.29B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -492.6M
and capital expenditures -297.7M, giving a free cash flow of -790.3M.
Operating Cash Flow -492.6M Capital Expenditures -297.7M Free Cash Flow -790.3M FCF Per Share -3.07
Full Cash Flow Statement Margins Gross margin is 86.11%, with operating and profit margins of -2.11% and -4.86%.
Gross Margin 86.11% Operating Margin -2.11% Pretax Margin 2.25% Profit Margin -4.86% EBITDA Margin 4.41% EBIT Margin -2.11% FCF Margin -7.17%
Dividends & Yields VRTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for VRTX is $490,
which is 30.9% higher than the current price. The consensus rating is "Buy".
Price Target $490 Price Target Difference 30.9% Analyst Consensus Buy Analyst Count 22
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 24, 2000. It was a
forward
split with a ratio of 2:1.
Last Split Date Aug 24, 2000 Split Type forward Split Ratio 2:1
Scores Altman Z-Score 10.6 Piotroski F-Score 7
